GENE ONLINE|News &
Opinion
Blog

2020-12-05| Asia-PacificCOVID-19

COVID-19: BioNTech Commences Phase 2 Vaccine Trials in China with Fosun

by Tyler Chen
Share To

BioNTech, once a frontrunner in the global vaccine race, gained emergency approval in the UK recently. As the mRNA vaccine (BNT162b2), co-developed with Pfizer, is found more than 95% effective in preventing COVID-19, BioNTech has turned to the Chinese market to collect clinical data of the vaccine for regulatory approval in China.

 

BNT162b2 Enters Phase 2 Trials in China

On November 25, BioNTech and Fosun Pharmaceutical (Fosun) announced the start of Phase 2 clinical trial in China to evaluate the safety and immunogenicity of BNT162b2. The trial will be conducted by Jiangsu Provincial Center for Disease Control and Prevention in Taizhou and Lianshui, Jiangsu Province, for biologics license application in China.

“As an important part of global research and development, the Phase 2 clinical study with BNT162b2 in China will not only provide key data for the launch of the vaccine in China but also may play a positive role in the widespread promotion and use of the vaccine throughout Asia and around the world.” President of Global Research and Development and Chief Medical Officer of Fosun Pharma Dr. Aimin Hui said.

 

Primary Endpoints

The trial involves 960 healthy adults (18 to 85 years old) who will be separated into 2 groups. While 720 subjects are intravenously injected with BNT162b2, the remaining 240 subjects will be given a placebo. The humoral immune responses of the participants will be examined 1 month after the second shots of vaccines. Besides, the safety and tolerability of BNT162b2 will be observed on the 7th and 14th day after every shot. The primary endpoint is to look at patients’ seroconversion rates (SCR) and geometric mean titer (GMT) of SARS-CoV-2 serum neutralizing titers.

 

Vaccine Strategies in China

Fosun is a healthcare company in China that strives to develop and manufacture innovative small molecule drugs, high-value generic drugs, biologics, and cell therapy.

Fosun became BioNTech’s strategic partner in China in March; the goal is to further develop and commercialize the COVID-19 vaccine. The two have commenced the phase 1 clinical trial of BNT162b1 in August, while on November 13, BNT162b2 received the green light from China regulatory authorities for clinical trials. Fosun announced in August that once BNT162 vaccines are approved, it will supply 10 million doses to Hong Kong and Macao.

By Tyler Chen

Related Article:Final Analysis Suggests Pfizer, BioNTech’s COVID-19 Vaccine is Safe with 95% Efficacy

References
  1. https://investors.biontech.de/news-releases/news-release-details/biontech-and-fosun-pharma-announce-start-phase-2-clinical-trial
  2. http://www.chictr.org.cn/showproj.aspx?proj=64544
  3. https://www.fosun.com/language/hk/p/51290.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Gland Pharma Dispels Rumors Of Fosun Sale, Acquires Cenexi In Separate Development
2022-11-30
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!